NasdaqGM - Delayed Quote USD

AtriCure, Inc. (ATRC)

32.30
+0.05
+(0.16%)
At close: May 15 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael H. Carrel CEO, President & Director 1.72M -- 1971
Ms. Angela L. Wirick Chief Financial Officer 781.04k 181.4k 1978
Mr. Douglas J. Seith Chief Operating Officer 1.05M -- 1966
Mr. Karl S. Dahlquist CCEP, J.D. Chief Legal Officer 707.11k -- 1971
Mr. Justin J. Noznesky Chief Marketing & Strategy Officer 712.5k -- 1978
Mr. Salvatore Privitera J.D. Chief Technical Officer 758.8k -- 1967
Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer 777.66k -- 1973
Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications -- -- --

AtriCure, Inc.

7555 Innovation Way
Mason, OH 45040
United States
513 755 4100 https://www.atricure.com
Sector: 
Healthcare
Full Time Employees: 
1,300

Description

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Corporate Governance

AtriCure, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 28, 2025 at 10:59 AM UTC - August 1, 2025 at 12:00 PM UTC

AtriCure, Inc. Earnings Date

Recent Events

May 5, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 30, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 29, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 7, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 26, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 12, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 30, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers